BRPI0914312A2 - composição e métodos de uso de orf 554 de cepas estreptocócicas beta hemolíticas - Google Patents

composição e métodos de uso de orf 554 de cepas estreptocócicas beta hemolíticas

Info

Publication number
BRPI0914312A2
BRPI0914312A2 BRPI0914312A BRPI0914312A BRPI0914312A2 BR PI0914312 A2 BRPI0914312 A2 BR PI0914312A2 BR PI0914312 A BRPI0914312 A BR PI0914312A BR PI0914312 A BRPI0914312 A BR PI0914312A BR PI0914312 A2 BRPI0914312 A2 BR PI0914312A2
Authority
BR
Brazil
Prior art keywords
orf
composition
methods
beta hemolytic
hemolytic strains
Prior art date
Application number
BRPI0914312A
Other languages
English (en)
Inventor
Sybil Anderson Annaliesa
Murphy Ellen
Braunstein Emily
Lea Dodge Ingrid
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI0914312A2 publication Critical patent/BRPI0914312A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0914312A 2008-06-20 2009-06-19 composição e métodos de uso de orf 554 de cepas estreptocócicas beta hemolíticas BRPI0914312A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7423908P 2008-06-20 2008-06-20
PCT/US2009/047886 WO2009155476A2 (en) 2008-06-20 2009-06-19 Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains

Publications (1)

Publication Number Publication Date
BRPI0914312A2 true BRPI0914312A2 (pt) 2017-05-30

Family

ID=41137027

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914312A BRPI0914312A2 (pt) 2008-06-20 2009-06-19 composição e métodos de uso de orf 554 de cepas estreptocócicas beta hemolíticas

Country Status (12)

Country Link
US (1) US7754226B2 (pt)
EP (2) EP2650015A2 (pt)
JP (1) JP2011525112A (pt)
KR (1) KR20110031337A (pt)
CN (1) CN102105165A (pt)
AU (1) AU2009259951A1 (pt)
BR (1) BRPI0914312A2 (pt)
CA (1) CA2728258A1 (pt)
IL (1) IL210068A0 (pt)
MX (1) MX2010014355A (pt)
RU (1) RU2010152003A (pt)
WO (1) WO2009155476A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074273A1 (es) * 2008-11-05 2011-01-05 Wyeth Corp Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2189473A3 (en) * 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
EP1421098A4 (en) * 2001-04-13 2006-03-15 Wyeth Corp SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES
DE602004022923D1 (de) * 2003-03-04 2009-10-15 Intercell Ag Streptococcus pyogenes antigene

Also Published As

Publication number Publication date
EP2303317A2 (en) 2011-04-06
US7754226B2 (en) 2010-07-13
CA2728258A1 (en) 2009-12-23
CN102105165A (zh) 2011-06-22
US20090318358A1 (en) 2009-12-24
KR20110031337A (ko) 2011-03-25
MX2010014355A (es) 2011-03-21
WO2009155476A2 (en) 2009-12-23
RU2010152003A (ru) 2012-07-27
WO2009155476A3 (en) 2010-03-11
IL210068A0 (en) 2011-02-28
AU2009259951A1 (en) 2009-12-23
EP2650015A2 (en) 2013-10-16
JP2011525112A (ja) 2011-09-15

Similar Documents

Publication Publication Date Title
SMT201500213B (it) Alcune triazolopirazine, loro composizioni e metodi d'uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI1014914A2 (pt) Composição contendo trehalulose, sua preparação e uso
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0912703A2 (pt) composições imuno-moduladoras e métodos para uso dessas
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
BRPI1007175A2 (pt) Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI0822997A2 (pt) Extratos imunomoduladores de bactérias lactobacillus e métodos para fabricação e uso dos mesmos
BRPI0907365A2 (pt) Composição antimicrobiana e uso
BR112012002982A2 (pt) uso de cosméticos de extratos de levedura salientados modificados e composições relacionadas.
BRPI1005670A2 (pt) composições adjuvantes e métodos de uso
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0812166A2 (pt) Composições úteis para reduzir nefrotoxicidade e métodos de uso das mesmas
BR112013014779A2 (pt) composição de filtro solar e uso
BRPI1006996A2 (pt) composição, método e uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]